A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

Những quyển sách tương tự

• Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
  Bằng: Kim, Tae Min, et al.
  Được phát hành: (2018)
• Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
  Bằng: Lee, Youngjoo, et al.
  Được phát hành: (2017)
• VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR‐Tyrosine Kinase Inhibitor‐Resistant Non‐Small Cell Lung Cancer
  Bằng: Sehwa Hong, et al.
  Được phát hành: (2025-09-01)
• Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
  Bằng: Ji, Wonjun, et al.
  Được phát hành: (2013)
• Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
  Bằng: Park, Ha Young, et al.
  Được phát hành: (2016)